SCHEMBL12410792

SCHEMBL12410792

CC(C)c1nnc(-c2ccccn2)[nH]1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 1/20 0.45
METAP1 P53582 6/20 0.44
METAP2 P50579 5/20 0.44
LMNA P02545 5/20 0.44
SMN1; SMN2 Q16637 5/20 0.44
NPC1 O15118 4/20 0.44
PKM P14618 4/20 0.44
RAB9A P51151 4/20 0.44
HPGD P15428 2/20 0.44
MTOR P42345 1/20 0.44
KDM4E B2RXH2 5/20 0.43
POLB P06746 2/20 0.43
CYP1A2 P05177 1/20 0.43
CCR1 P32246 1/20 0.43
CCR5 P51681 1/20 0.43
CCR8 P51685 1/20 0.43
BLM P54132 1/20 0.43
HIF1A Q16665 1/20 0.43
DOHH Q9BU89 1/20 0.43
P4HTM Q9NXG6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5478697 0.81 KDM4E (0.59) BTKMETAP1METAP2LMNASMN1; SMN2
SCHEMBL13341373 0.80 SLC6A2 (0.44) BTKMETAP1METAP2LMNASMN1; SMN2
SCHEMBL8525906 0.78 HTT (0.50) BTKMETAP1METAP2LMNASMN1; SMN2
SCHEMBL420934 0.77 KDM4E (0.54) BTKMETAP1METAP2LMNASMN1; SMN2
SCHEMBL9963177 0.76 METAP2 (0.41) METAP2LMNASMN1; SMN2CYP1A2NPY5R
SCHEMBL12197775 0.74 POLB (0.50) BTKLMNANPC1RAB9AHPGD
SCHEMBL28014813 0.74 SMN1; SMN2 (0.59) BTKMETAP1METAP2LMNASMN1; SMN2
SCHEMBL19077866 0.74 NPY5R (0.47) BTKMETAP1METAP2LMNASMN1; SMN2
SCHEMBL23222296 0.74 METAP1 (0.47) BTKMETAP1METAP2LMNASMN1; SMN2
SCHEMBL19935423 0.74 CBFB (0.47) BTKMETAP1METAP2LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023148481-A1 SMO MODULATOR COMPOUNDS Omass Therapeutics Limited (GB) 2023-08-10 WO disclosed
US-8497278-B2 Imidazo[1,2-a]pyridine compounds SUNOVION PHARMACEUTICALS INC. (US) 2013-07-30 US disclosed
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. (US) 2011-07-07 US disclosed
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD BTK 2373/4885METAP1 2586/4885METAP2 1746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.